McKesson Corporation (MCK) Stock Analysis
Healthcare · Medical Distribution
Sell if holding. Engine safety override at $761.89: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.
McKesson is a diversified healthcare services company with four segments—North American Pharmaceutical distribution, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—serving pharmacies, hospitals, and providers across North America.... Read more
Sell if holding. Engine safety override at $761.89: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.9/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent Developments — McKesson Corporation
Material events (past 30 days)
- Apr 28, 2026 MEDIUM Item 1.02: McKesson terminated its existing $1.0B 364-day and $4.0B five-year revolving credit facilities on April 24, 2026, replacing them with a new consolidated $5B revolving credit facility. Successor agreement in place.
Latest news
- 'Merck Starts Seven-Part High-Grade Bond Sale to Fund Terns Deal' - Bloomberg — benzinga May 18, 2026 neutral
- Citigroup Maintains Buy on McKesson, Lowers Price Target to $945 — benzinga May 14, 2026 positive
- Wells Fargo Maintains Equal-Weight on McKesson, Lowers Price Target to $812 — benzinga May 12, 2026 neutral
- UBS Maintains Buy on McKesson, Raises Price Target to $1050 — benzinga May 8, 2026 positive
- JP Morgan Maintains Overweight on McKesson, Lowers Price Target to $1015 — benzinga May 8, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-28Item 1.02MEDIUMMcKesson terminated its existing $1.0B 364-day and $4.0B five-year revolving credit facilities on April 24, 2026, replacing them with a new consolidated $5B revolving credit facility. Successor agreement in place.SEC filing →
- 2026-03-05Item 5.02MEDIUMCFO Britt J. Vitalone gave notice of retirement; last day as CFO May 28, 2026. Kenny K. Cheung (former CFO of Sysco) appointed new CFO effective May 29, 2026. Clean handoff.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $761.89: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $711.39. Score 5.9/10, moderate confidence.
Take-profit target: $854.76 (+12.2% upside). Prior stop was $711.39. Stop-loss: $711.39.
Quality below floor (3.5 < 4.0).
McKesson Corporation trades at a P/E of 20.2 (forward 15.4). TrendMatrix value score: 6.9/10. Verdict: Sell.
23 analysts cover MCK with a consensus score of 4.2/5. Average price target: $950.
What does McKesson Corporation do?McKesson is a diversified healthcare services company with four segments—North American Pharmaceutical distribution,...
McKesson is a diversified healthcare services company with four segments—North American Pharmaceutical distribution, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—serving pharmacies, hospitals, and providers across North America. With 43,000+ employees and 27 U.S. pharmaceutical distribution centers, it has announced plans to separate its Medical-Surgical segment.